[go: up one dir, main page]

TNSN00203A1 - Derives de purine nouveaux, procede pour leur preparation et des compositions les contenant - Google Patents

Derives de purine nouveaux, procede pour leur preparation et des compositions les contenant

Info

Publication number
TNSN00203A1
TNSN00203A1 TNTNSN00203A TNSN00203A TNSN00203A1 TN SN00203 A1 TNSN00203 A1 TN SN00203A1 TN TNSN00203 A TNTNSN00203 A TN TNSN00203A TN SN00203 A TNSN00203 A TN SN00203A TN SN00203 A1 TNSN00203 A1 TN SN00203A1
Authority
TN
Tunisia
Prior art keywords
preparation
compositions containing
purine derivatives
new purine
compounds
Prior art date
Application number
TNTNSN00203A
Other languages
English (en)
Inventor
Marina Monaghan Sandra
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN00203A1 publication Critical patent/TNSN00203A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSES DE FORMULE I : DANS LAQUELLE R1, R2 ET R7 REPRESENTENT L'HYDROGENE OU DIVERS RADICAUX ORGANIQUES, ET A REPRESENTE UNE LIAISON OU UN RADICAL ORGANIQUE. ELLE CONCERNE EGALEMENT DES PROCEDES POUR LEUR PREPARATION, LES INTERMEDIAIRES UTILISES, ET DES COMPOSITIONS LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS COMME AGONISTES DES RECEPTEURS D'ADENOSINE A2a POUR LE TRAITEMENT DE DIVERSES MALADIES.
TNTNSN00203A 1999-10-14 2000-10-13 Derives de purine nouveaux, procede pour leur preparation et des compositions les contenant TNSN00203A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9924361.0A GB9924361D0 (en) 1999-10-14 1999-10-14 Purine derivatives

Publications (1)

Publication Number Publication Date
TNSN00203A1 true TNSN00203A1 (fr) 2002-05-30

Family

ID=10862758

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00203A TNSN00203A1 (fr) 1999-10-14 2000-10-13 Derives de purine nouveaux, procede pour leur preparation et des compositions les contenant

Country Status (43)

Country Link
US (1) US6448236B1 (fr)
EP (1) EP1220862B1 (fr)
JP (1) JP3994008B2 (fr)
KR (1) KR20030022758A (fr)
CN (1) CN1166678C (fr)
AP (1) AP2002002480A0 (fr)
AR (1) AR026052A1 (fr)
AT (1) ATE321065T1 (fr)
AU (1) AU771531B2 (fr)
BG (1) BG106567A (fr)
BR (1) BR0014760A (fr)
CA (1) CA2387533C (fr)
CO (1) CO5261621A1 (fr)
CR (1) CR6607A (fr)
CZ (1) CZ20021179A3 (fr)
DE (1) DE60026861T2 (fr)
EA (1) EA004985B1 (fr)
EC (1) ECSP003713A (fr)
EE (1) EE200200194A (fr)
ES (1) ES2257317T3 (fr)
GB (1) GB9924361D0 (fr)
GE (1) GEP20043324B (fr)
GT (2) GT200000170A (fr)
HK (1) HK1047942B (fr)
HR (1) HRP20020325A2 (fr)
HU (1) HUP0203485A3 (fr)
IL (1) IL148331A0 (fr)
IS (1) IS6287A (fr)
MA (1) MA26829A1 (fr)
MX (1) MXPA02003750A (fr)
MY (1) MY141512A (fr)
NO (1) NO20021751L (fr)
NZ (1) NZ517294A (fr)
OA (1) OA12060A (fr)
PA (1) PA8503601A1 (fr)
PE (1) PE20010753A1 (fr)
PL (1) PL354880A1 (fr)
SK (1) SK4742002A3 (fr)
SV (1) SV2002000199A (fr)
TN (1) TNSN00203A1 (fr)
TR (1) TR200201001T2 (fr)
WO (1) WO2001027131A1 (fr)
ZA (1) ZA200202725B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
GB0015727D0 (en) * 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US20050033044A1 (en) 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP1728793B1 (fr) 2004-03-26 2016-02-03 Sumitomo Dainippon Pharma Co., Ltd. Compose 8-oxoadenine 9-substitue
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP2221307A1 (fr) 2004-05-26 2010-08-25 Inotek Pharmaceuticals Corporation Derivés de purines agonistes du récepteur adénosine A1 et leur utilisation
NZ554506A (en) * 2004-09-20 2011-01-28 Inotek Pharmaceuticals Corp Purine derivatives and methods of use thereof
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1957530A2 (fr) 2005-10-21 2008-08-20 Novartis AG Anticorps humains contre l'il-13 et ses utilisations therapeutiques
US7732424B2 (en) * 2005-11-30 2010-06-08 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2013211E (pt) * 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
WO2008004948A1 (fr) 2006-07-05 2008-01-10 Astrazeneca Ab Dérivés de la 8-oxoadénine agissant comme modulateurs de tlr7
EP2081933B1 (fr) 2006-09-29 2011-03-23 Novartis AG PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
MX2009004715A (es) 2006-10-30 2009-05-20 Novartis Ag Compuestos heterociclicos como agentes antiinflamatorios.
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
US20100105652A1 (en) * 2007-03-02 2010-04-29 Glaxo Group Limited Purines as cysteine protease inhibitors
PT2132209E (pt) * 2007-03-19 2014-04-15 Astrazeneca Ab Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
US8063051B2 (en) * 2007-03-19 2011-11-22 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators
US8044056B2 (en) 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
PE20081887A1 (es) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
MY150519A (en) * 2007-05-08 2014-01-30 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
UY31531A1 (es) 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
WO2009091031A1 (fr) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. Procédé de production d'un composé d'adénine
WO2009091032A1 (fr) 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. Procédé de production d'un composé d'adénine
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
AU2010284254B2 (en) 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
JP2013512859A (ja) * 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
SI2523669T1 (sl) 2010-01-11 2017-05-31 Inotek Pharmaceuticals Corporation Kombinacija, komplet in metoda za zmanjšanje intraokularnega tlaka
SG184221A1 (en) 2010-03-26 2012-10-30 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
ES2575688T3 (es) 2010-12-16 2016-06-30 Sumitomo Dainippon Pharma Co., Ltd. Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia
JP5978226B2 (ja) 2010-12-17 2016-08-24 大日本住友製薬株式会社 プリン誘導体
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
SG11201403979TA (en) 2012-01-26 2014-08-28 Inotek Pharmaceuticals Corp Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
SG11201506882YA (en) 2013-03-15 2015-09-29 Inotek Pharmaceuticals Corp Ophthalmic formulations
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
CA3102279A1 (fr) 2018-06-01 2019-12-05 Cornell University Polytherapie pour maladie ou trouble associe a pi3k
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5536419A (en) * 1978-09-08 1980-03-14 Yamasa Shoyu Co Ltd 2-substituted adenosine derivative and its preparation
AU8276187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
BR9914526A (pt) * 1998-10-16 2001-07-03 Pfizer Derivados de adenina
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives

Also Published As

Publication number Publication date
HK1047942A1 (zh) 2003-03-14
GB9924361D0 (en) 1999-12-15
CZ20021179A3 (cs) 2003-04-16
JP2003511460A (ja) 2003-03-25
AR026052A1 (es) 2002-12-26
CN1378551A (zh) 2002-11-06
MXPA02003750A (es) 2003-10-14
AU771531B2 (en) 2004-03-25
PE20010753A1 (es) 2001-07-17
CO5261621A1 (es) 2003-03-31
MA26829A1 (fr) 2004-12-20
CN1166678C (zh) 2004-09-15
NO20021751D0 (no) 2002-04-12
GEP20043324B (en) 2004-04-13
GT200000170A (es) 2002-04-03
EA200200360A1 (ru) 2002-10-31
HUP0203485A2 (hu) 2003-03-28
CA2387533C (fr) 2007-03-13
AP2002002480A0 (en) 2002-06-30
CA2387533A1 (fr) 2001-04-19
KR20030022758A (ko) 2003-03-17
JP3994008B2 (ja) 2007-10-17
EE200200194A (et) 2003-06-16
HRP20020325A2 (en) 2004-04-30
WO2001027131A1 (fr) 2001-04-19
DE60026861T2 (de) 2006-09-21
IS6287A (is) 2002-02-26
EP1220862A1 (fr) 2002-07-10
BR0014760A (pt) 2002-07-02
SK4742002A3 (en) 2003-05-02
HUP0203485A3 (en) 2005-02-28
AU7441200A (en) 2001-04-23
EA004985B1 (ru) 2004-10-28
ES2257317T3 (es) 2006-08-01
BG106567A (en) 2002-12-29
ATE321065T1 (de) 2006-04-15
ECSP003713A (es) 2002-05-23
MY141512A (en) 2010-05-14
PL354880A1 (en) 2004-03-22
EP1220862B1 (fr) 2006-03-22
US6448236B1 (en) 2002-09-10
DE60026861D1 (de) 2006-05-11
SV2002000199A (es) 2002-02-05
OA12060A (en) 2006-05-03
HK1047942B (zh) 2005-04-01
IL148331A0 (en) 2002-09-12
ZA200202725B (en) 2003-04-08
GT200000173A (es) 2002-04-05
NO20021751L (no) 2002-06-13
PA8503601A1 (es) 2002-02-21
TR200201001T2 (tr) 2002-09-23
NZ517294A (en) 2004-03-26
CR6607A (es) 2003-11-25

Similar Documents

Publication Publication Date Title
TNSN00203A1 (fr) Derives de purine nouveaux, procede pour leur preparation et des compositions les contenant
TNSN00202A1 (fr) Derives de n-[(purine - 2- yl) methyl]-sulfonamide nouveaux, procede pour leur preparation et compositions les contenant
TNSN01028A1 (fr) Derives de purine nouveaux, procede pour leur preparation et compositions les contenant
TNSN01134A1 (fr) Derives de purine nouveaux, procede pour leur preparation et compositions les contenant.
TNSN01096A1 (fr) Derives de purines nouveaux, procede pour leur preparation et compositions les contenant
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN02012A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN02010A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN01077A1 (fr) Derives de tropane nouveaux, procede pour leur preparation et compositions les contenant
MA26718A1 (fr) Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN02021A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
MA26696A1 (fr) Derives de tetrahydrobenzazepine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98066A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00065A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant.
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99156A1 (fr) Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA27121A1 (fr) Derives 2-(purin-9-yl)-tetrahydrofuran-3,4-diol
TNSN97145A1 (fr) Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
TNSN02008A1 (fr) Derives d'acides isophtalique nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN01131A1 (fr) Derives de phenoxybenzylamine nouveaux, procede pour leur preparation et compositions les contenant.